{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:45:51Z","timestamp":1778946351730,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["GH002154"],"award-info":[{"award-number":["GH002154"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The World Health Organization (WHO) recommends routine surveillance of pretreatment human immunodeficiency virus (HIV) drug resistance (HIVDR) in children &amp;lt;18 months of age diagnosed with HIV through early infant diagnosis (EID). In 2016, 262 children &amp;lt;18 months of age were diagnosed with HIV in Namibia through EID. Levels of HIVDR in this population are unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In 2016, Namibia surveyed pretreatment HIVDR among children aged &amp;lt;18 months following WHO guidance. Reverse transcriptase, protease, and integrase regions of HIV-1 were genotyped from remnant dried blood spot specimens from all infants diagnosed with HIV in Namibia in 2016. HIVDR was predicted using the Stanford HIVdb algorithm.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 262 specimens genotyped, 198 HIV-1 protease and reverse transcriptase sequences and 118 HIV-1 integrase sequences were successfully amplified and analyzed. The prevalence of efavirenz\/nevirapine (EFV\/NVP), abacavir (ABC), zidovudine, lamivudine\/emtricitabine (3TC\/FTC), and tenofovir (TDF) resistance was 62.6%, 17.7%, 5.6%, 15.7%, and 10.1%, respectively. No integrase inhibitor resistance was detected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The high level of EFV\/NVP resistance is unsurprising; however, levels of ABC and TDF resistance are among the highest observed to date in infants in sub-Saharan Africa. The absence of resistance to dolutegravir (DTG) is reassuring but underscores the need to further study the impact of ABC and 3TC\/FTC resistance on pediatric protease inhibitor\u2013 and DTG-based regimens and accelerate access to other antiretroviral drugs. Results underscore the need for antiretroviral therapy optimization and prompt management of high viral loads in infants and pregnant and breastfeeding women.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofac102","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T17:50:21Z","timestamp":1648230621000},"source":"Crossref","is-referenced-by-count":4,"title":["Pretreatment Human Immunodeficiency Virus (HIV) Drug Resistance Among Treatment-Naive Infants Newly Diagnosed With HIV in 2016 in Namibia: Results of a Nationally Representative Study"],"prefix":"10.1093","volume":"9","author":[{"given":"Michael R","family":"Jordan","sequence":"first","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, USA"},{"name":"Levy Center for Integrated Management of Antimicrobial Resistance, Tufts University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Bikinesi","sequence":"additional","affiliation":[{"name":"Directorate of Special Programmes, Republic of Namibia Ministry of Health and Social Services, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laimi","family":"Ashipala","sequence":"additional","affiliation":[{"name":"Directorate of Special Programmes, Republic of Namibia Ministry of Health and Social Services, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholus","family":"Mutenda","sequence":"additional","affiliation":[{"name":"Directorate of Special Programmes, Republic of Namibia Ministry of Health and Social Services, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Brantuo","sequence":"additional","affiliation":[{"name":"World Health Organization, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Hunt","sequence":"additional","affiliation":[{"name":"Centre for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Shiningavamwe","sequence":"additional","affiliation":[{"name":"Namibia Institute of Pathology, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gram","family":"Mutandi","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Beukes","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Beard","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Windhoek, Namibia"},{"name":"Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Battey","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Windhoek, Namibia"},{"name":"Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J","family":"Dziuban","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5121-877X","authenticated-orcid":false,"given":"Elliot","family":"Raizes","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Adjei","sequence":"additional","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Giron","sequence":"additional","affiliation":[{"name":"Department of Global HIV, Hepatitis and STI Programmes, World Health Organization, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven Y","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Global HIV and TB, Center for Global Health, Centers for Disease Control and Prevention, Windhoek, Namibia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,24]]},"reference":[{"key":"2022041403081784700_CIT0001","year":"2018"},{"key":"2022041403081784700_CIT0002","year":"2021"},{"key":"2022041403081784700_CIT0003","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/QAD.0000000000000261","article-title":"Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis.","volume":"28","author":"Kuhn","year":"2014","journal-title":"AIDS"},{"key":"2022041403081784700_CIT0004","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S0140-6736(04)17140-7","article-title":"Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis.","volume":"364","author":"Newell","year":"2004","journal-title":"Lancet"},{"key":"2022041403081784700_CIT0005","doi-asserted-by":"crossref","first-page":"e28510","DOI":"10.1371\/journal.pone.0028510","article-title":"Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis.","volume":"7","author":"Becquet","year":"2012","journal-title":"PLoS One"},{"key":"2022041403081784700_CIT0006","doi-asserted-by":"crossref","first-page":"7120","DOI":"10.1128\/JVI.77.12.7120-7123.2003","article-title":"Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection.","volume":"77","author":"Richardson","year":"2003","journal-title":"J Virol"},{"key":"2022041403081784700_CIT0007","doi-asserted-by":"crossref","first-page":"21140","DOI":"10.7448\/IAS.19.1.21140","article-title":"High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children.","volume":"19","author":"Boerma","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"2022041403081784700_CIT0008","volume-title":"Updated Recommendations on HIV Prevention, Infant Diagnosis, Antiretroviral Initiation and Monitoring","author":"World Health Organization.","year":"2021"},{"key":"2022041403081784700_CIT0009","volume-title":"Surveillance of HIV Drug Resistance in Children Newly Diagnosed With HIV by Early Infant Diagnosis","author":"World Health Organization.","year":"2017"},{"key":"2022041403081784700_CIT0010","first-page":"14","volume-title":"Updated Guidance on First-Line and Second-Line Antiretroviral Regimens","author":"World Health Organization.","year":"2019"},{"key":"2022041403081784700_CIT0011","volume-title":"National Guidelines for Antiretroviral Therapy","year":"2016"},{"key":"2022041403081784700_CIT0012","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/QAI.0000000000001553","article-title":"High prevalence of HIV drug resistance among newly diagnosed infants aged &lt;18 months: results from a nationwide surveillance in Nigeria.","volume":"77","author":"Inzaule","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022041403081784700_CIT0013","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jac\/dkw463","article-title":"Alarming increase in pretreatment HIV drug resistance in children living in sub-Saharan Africa: a systematic review and meta-analysis.","volume":"72","author":"Boerma","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2022041403081784700_CIT0014","first-page":"26","volume-title":"WHO Manual for HIV Drug Resistance Testing Using Dried Blood Spot Specimens","author":"World Health Organization.","year":"2012"},{"key":"2022041403081784700_CIT0015","doi-asserted-by":"crossref","first-page":"e28184","DOI":"10.1371\/journal.pone.0028184","article-title":"Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings.","volume":"6","author":"Zhou","year":"2011","journal-title":"PLoS One"},{"key":"2022041403081784700_CIT0016","volume-title":"WHO HIVDR QC tool","author":"Woods","year":"2021"},{"key":"2022041403081784700_CIT0017","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database.","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2022041403081784700_CIT0018","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation.","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2022041403081784700_CIT0019","year":"2019"},{"key":"2022041403081784700_CIT0020","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"2022041403081784700_CIT0021","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"Integrase strand transfer inhibitor (INSTI)\u2013resistance mutations for the surveillance of transmitted HIV-1 drug resistance.","volume":"75","author":"Tzou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022041403081784700_CIT0022","first-page":"68","volume-title":"HIV Drug Resistance Report 2019","author":"World Health Organization.","year":"2019"},{"key":"2022041403081784700_CIT0023","volume-title":"Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach","author":"World Health Organization.","year":"2021"},{"key":"2022041403081784700_CIT0024","volume-title":"Considerations for Developing a Monitoring and Evaluation Framework for Viral Load Testing","author":"World Health Organization.","year":"2019"},{"key":"2022041403081784700_CIT0025","first-page":"48","volume-title":"HIV Molecular Diagnostics Toolkit to Improve Access to Viral Load Testing and Infant Diagnosis","author":"World Health Organization.","year":"2019"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofac102\/42993862\/ofac102.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/5\/ofac102\/43377107\/ofac102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/9\/5\/ofac102\/43377107\/ofac102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T03:08:41Z","timestamp":1649905721000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofac102\/6553341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,24]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofac102","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,3,24]]},"article-number":"ofac102"}}